Drugs / Carbetocin
Carbetocin
also known as
Pabal · 1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin · Carbetocina · Carbetocine · Duratocin · Duratocin for carbetocin · Duratocin long acting · FE 992097 · +1 more
Trials 39
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02396303 | Jun → Oct 2015 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05924321 | May → Sep 2023 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05986266 | Feb → Aug 2023 | uterine benign neoplasm | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06217354 | Jul → Oct 2023 | obesity disorder | Cairo University | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT01968187 | Jan → Jul 2014 | Prader-Willi syndrome | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT02079558 | Sep 2012 → Sep 2013 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06420297 | Mar 2024 → May 2029 expected | Prader-Willi syndrome | ACADIA Pharmaceuticals Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06173531 | Nov 2023 → Oct 2025 overdue | Prader-Willi syndrome | ACADIA Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03649477 | Nov 2018 → May 2020 | Prader-Willi syndrome | Levo Therapeutics, Inc. | Completed | Mixed |
| Phase 3 | NCT02216383 | Feb 2015 → Aug 2018 | — | North Bristol NHS Trust | Completed | No outcome recorded |
| Phase 3 | NCT01382732 | Jan 2012 → Dec 2015 | severe pre-eclampsia | Saint Thomas Hospital, Panama | Unknown | No outcome recorded |
| Phase 418 trials · 3 met primary · 1 missed | ||||||
| Phase 4 | NCT07401524 | May 2026 → Mar 2028 expected | pregnancy disorder | Sheba Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06946589 | Aug 2025 → Aug 2026 overdue | myocardial ischemia | Jordan Leitch | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05664659 | Dec 2022 → Apr 2023 | — | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04595812 | Nov 2020 → Aug 2022 | uterine corpus leiomyoma | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04482959 | Jul 2020 → Dec 2021 | leiomyoma | Mansoura University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04083625 | Sep 2019 → Feb 2020 | leiomyoma | Cairo University | Completed | Met primary |
| Phase 4 | NCT03899961 | Apr 2019 → Mar 2022 | pregnancy disorder | Oslo University Hospital | Completed | Missed primary |
| Phase 4 | NCT02642263 | Feb 2019 → Dec 2020 | — | Insel Gruppe AG, University Hospital Bern | Unknown | No outcome recorded |
| Phase 4 | NCT03716076 | Nov 2018 → Jun 2019 | cardiac rhythm disease | University of British Columbia | Completed | Met primary |
| Phase 4 | NCT03693599 | Oct 2018 → Sep 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03755531 | Jan → Jun 2018 | — | Al-Kindy College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02636816 | Mar → Jun 2016 | pregnancy disorder | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT02528136 | Sep 2015 → Jan 2019 | pregnancy disorder | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02391636 | Feb 2015 → Sep 2016 | — | Ghamra Military Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02221531 | Aug 2014 → Nov 2015 | — | University Hospital, Basel, Switzerland | Completed | Met primary |
| Phase 4 | NCT01827124 | Apr → Nov 2013 | — | Wafaa Uthman Ahmed | Unknown | No outcome recorded |
| Phase 4 | NCT01579201 | Mar 2012 → Mar 2013 | uterine disorder | Maisonneuve-Rosemont Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00977769 | Nov 2009 → Aug 2011 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase not applicable10 trials · 1 met primary | ||||||
| — | NCT07353281 | Jan 2026 → Jan 2028 expected | puerperal disorder | Western Galilee Hospital-Nahariya | Not yet recruiting | No outcome recorded |
| — | NCT07390864 | Jan → Jul 2026 overdue | leiomyoma | Cairo University | Recruiting | No outcome recorded |
| — | NCT07380529 | Oct 2024 → Aug 2025 | pregnancy disorder | Ankara Etlik City Hospital | Completed | No outcome recorded |
| — | NCT06060327 | Oct 2023 → Jun 2024 | — | Cairo University | Completed | No outcome recorded |
| — | NCT05467462 | Aug 2022 → Jan 2023 | — | Bezmialem Vakif University | Completed | No outcome recorded |
| — | NCT05083910 | Jul 2021 → Jan 2022 | — | Bezmialem Vakif University | Completed | Met primary |
| — | NCT04201665 | Sep 2020 → Jan 2022 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT04756661 | Jan → Dec 2020 | severe pre-eclampsia | Assiut University | Completed | No outcome recorded |
| — | NCT03578263 | Apr 2018 → Mar 2020 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT01719952 | Jan 2012 → Dec 2013 | pregnancy disorder | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Comparator or background therapy50 trials | ||||||
| Phase 0 | NCT04089176 Comparator | Feb → Apr 2019 | — | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| Phase 2/3 | NCT02786992 Comparator | May 2016 → Jan 2020 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT02410759 Comparator | Apr 2015 → Mar 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02304042 Comparator | Nov 2014 → Jul 2015 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT02303418 Comparator | Nov 2014 → Nov 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02304055 Comparator | May 2013 → Dec 2014 | obstetric disorder | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT02086994 Comparator | Mar 2013 → Aug 2015 | severe pre-eclampsia | khalid abd aziz mohamed | Completed | No outcome recorded |
| Phase 3 | NCT02053922 Comparator | Dec 2012 → Aug 2013 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT07636421 Background | Aug 2026 → Apr 2028 expected | uterine disorder | Mansoura University | Recruiting | No outcome recorded |
| Phase 4 | NCT05806307 Comparator | Mar → Oct 2023 | drug pseudoallergy, uterine corpus leiomyoma | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT05742854 Comparator | Mar → May 2023 | — | Ege University | Unknown | No outcome recorded |
| Phase 4 | NCT05110482 Comparator | Nov 2021 → Jun 2023 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04357015 Comparator | May → Oct 2020 | leiomyoma | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03651882 Comparator | Aug 2018 → Jan 2022 | — | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT03556852 Comparator | Jul 2018 → May 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03404544 Comparator | Jun 2018 → Jan 2020 | — | Ciusss de L'Est de l'Île de Montréal | Completed | No outcome recorded |
| Phase 4 | NCT04300452 Comparator | Apr 2018 → Jun 2020 | — | National and Kapodistrian University of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT02277067 Comparator | Oct 2014 → Aug 2021 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 4 | NCT02277041 Comparator | Oct 2014 → Apr 2021 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 4 | NCT02044549 Comparator | Jun 2014 → Dec 2015 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02101567 Comparator | May 2014 → Apr 2015 | anemia, hemorrhagic disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT01630187 Comparator | Apr → Jul 2012 | uterine disorder | Laval University | Completed | No outcome recorded |
| Phase 4 | NCT00499005 Comparator | Nov 2006 → Apr 2009 | — | National University Hospital, Singapore | Completed | No outcome recorded |
| — | NCT07318467 Comparator | Jan → Jun 2026 overdue | — | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT07187544 Comparator | Dec 2025 → Dec 2026 expected | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT06930391 Comparator | Sep 2025 → Jun 2026 overdue | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT06333340 Comparator | Jan 2025 → Dec 2026 expected | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT06285409 Comparator | Apr 2024 → Dec 2026 expected | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT05479357 Comparator | Jul → Dec 2022 | pregnancy disorder | Sohag University | Unknown | No outcome recorded |
| — | NCT05154279 Comparator | Feb 2022 → Dec 2024 | uterine corpus leiomyoma | Wael Elbanna Clinic | Unknown | No outcome recorded |
| — | NCT05242783 Comparator | Feb 2022 → Mar 2024 | leiomyoma | Wael Elbanna Clinic | Completed | No outcome recorded |
| — | NCT05266534 Comparator | Dec 2021 → Jun 2024 overdue | leiomyoma | Wael Elbanna Clinic | Recruiting | No outcome recorded |
| — | NCT04182360 Comparator | Oct 2021 → Apr 2023 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT04902729 Comparator | Jul 2021 → Dec 2022 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT03870256 Comparator | Apr 2019 → Aug 2021 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03870503 Comparator | Apr 2019 → Jun 2021 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03777878 Comparator | Jan 2019 → Mar 2021 | — | Aswan University Hospital | Unknown | No outcome recorded |
| — | NCT03710317 Comparator | Dec 2018 → May 2020 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03708497 Comparator | Dec 2018 → May 2020 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03672045 Comparator | Nov 2018 → May 2019 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT03168698 Comparator | May 2017 → Dec 2020 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT02861482 Background | Jan 2015 → Mar 2016 | — | Dongyu Wang | Completed | No outcome recorded |
| — | NCT02264769 Comparator | Oct 2014 → Apr 2015 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01918475 Comparator | Jul 2013 → Dec 2014 | — | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| — | NCT01725243 Comparator | Nov 2012 → Mar 2013 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01600612 Comparator | Sep 2012 → Jun 2013 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT01651130 Comparator | Jun → Aug 2012 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01428817 Comparator | Jun → Dec 2011 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01262742 Comparator | Nov 2010 → Mar 2011 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT01689298 Comparator | Jan 2010 → Mar 2012 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-24 | ACADIA Pharmaceuticals Inc. | Results Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint acadia.com ↗
Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint. |
| 2020-05-13 | Ferring Pharmaceuticals | Regulatory Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births ferring.com ↗
Ferring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-24 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint acadia.com ↗ |
| 2023-11-30 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome acadia.com ↗ |
| 2023-06-13 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome acadia.com ↗ |
| 2021-07-26 | Ferring Pharmaceuticals | Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth ferring.com ↗ |
| 2020-05-13 | Ferring Pharmaceuticals | Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births ferring.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 91 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carbetocin | “In carbetocin group (n=111) 100 microgram carbetocin (Pabal, Ferring, Kiel, Germany) will be given as an intravenous bolus dose following the delivery of the placenta.” NCT06060327 ↗86“The efficacy and safety of i.n. carbetocin, an oxytocin analog, was evaluated in a prospective, randomized, double-blinded trial in adolescents with PWS.” PMID 29925684 ↗ Jun 2018 “100-mg carbetocin (Synpitan forte®; Deva Pharma, Istanbul, Turkey) was intravenously administered immediately after birth of the baby” NCT05083910 ↗ “intramyometrial Carbetocin injection in women undergoing open myomectomy procedure using haemostatic tourniquets.” NCT05242783 ↗ “Carbetocin is an Oxytocin derivative exerting effect via the same molecular mechanisms as Oxytocin.” NCT05154279 ↗ |
| Known as | 1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin | “Carbetocin (1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin” NCT04482959 ↗ |
| Known as | Carbetocina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301668 ↗ |
| Known as | Carbetocine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301668 ↗ |
| Known as | Duratocin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02861482 ↗ |
| Known as | Duratocin for carbetocin | “Duratocin for carbetocin” NCT01719952 ↗ |
| Known as | Duratocin long acting | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301668 ↗ |
| Known as | FE 992097 | “contained 1.6 mg carbetocin (FE 992097); each dose consisted of 3 spray pump actuations in each nostril that delivered a total of 9.6 mg carbetocin.” NCT01968187 ↗ |
| Known as | LV-101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301668 ↗ |
| Known as | Pabal | “The aim of this study is to compare the effectiveness of oxytocin or the long-acting oxytocin analog carbetocin (Pabal) administered to pregnant women to prevent postpartum...” NCT07380529 ↗12“Carbetocin group (C) received 1 ampoule of Carbetocin (100 μg/ml) (Pabal®, Draxis/Multipharma, Egypt, under license from DRAXIS PHARMA-Canada) added to 10 cc saline and given...” NCT03556852 ↗ “In carbetocin group (n=111) 100 microgram carbetocin (Pabal, Ferring, Kiel, Germany) will be given as an intravenous bolus dose following the delivery of the placenta.” NCT06060327 ↗ “Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive ergometrine 0.5mg (methergin®, Novartis, Switzerland).” NCT02410759 ↗ “Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.” NCT04201665 ↗ “single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).” NCT03693599 ↗ “Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland).” NCT02303418 ↗ “Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal” NCT01719952 ↗ “100 mcg IV carbetocin (Pabal; Ferring Pharmaceuticals) in 10 mL saline solution.” NCT05986266 ↗ “Group I: carbetocin (Pabal®; Ferring Pharma, Istanbul, Turkey)” NCT05467462 ↗ “Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK)” NCT02304042 ↗ |
| Action | Activate | “oxytocin agonist (carbetocin) appears to be the most promising for this indication” NCT00499005 ↗ |
| Modality | Peptide | “It is a long-acting synthetic octapeptide analogue of oxytocin with agonist properties.” NCT00499005 ↗ |
| Route | Intramuscular | “Intramuscular carbetocin is as effective as intramuscular syntometrine for the prevention of postpartum haemorrhage” NCT00499005 ↗ |
| Target | OXTR | “Carbetocin selectively binds to oxytocin receptors in the smooth muscle of the uterus resulting in rhythmic uterine contractions” NCT04595812 ↗ |